Although most patients with NSCLC positive for EML4–ALK derive benefit from treatment with ALK-TKIs, the clinical efficacy of these drugs varies greatly among such individuals and the molecular mechanism underlying this variability has been unclear. The gene discussed is EML4; the disease is non-small cell lung carcinoma.